Description
OKI-219 is an experimental drug currently being studied in clinical trials for certain types of advanced solid tumors and breast cancer. It is being investigated as a potential treatment option, either alone or in combination with other cancer drugs. In colorectal cancer trials, OKI-219 is being studied in patients whose tumors have specific genetic changes, such as HER2 or MET mutations, and who do not have KRAS mutations (KRAS wild-type). The goal of these early-phase trials is primarily to determine the safe dosage of OKI-219 and to see if it has any anti-cancer activity. It is not yet approved for use in colorectal cancer or any other cancer.
Mechanism of Action
OKI-219 is being studied as a potential cancer treatment. The specific way it works (its mechanism of action) is still under investigation in clinical trials. It is designed to target processes involved in cancer cell growth and survival. Researchers are evaluating how OKI-219 affects cancer cells and the body's response to it.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.